retatrutide phase 2 results obesity nejm 2023 Trial of for TRIUMPH-1 Trial Results: Retatrutide for

The adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has skyrocketed over the past few years, ushering in a new era of weight management and type 2 diabetes mellitus (T2DM) care

AOD-9604 demonstrated a genuine, statistically significant fat-loss effect in a smaller 12-week trial

Research-grade peptide

For those interested in exploring Retatrutide as a treatment option, Better You Rx provides resources to help you get started

Fun fact: the FDA does not consider a medication commercially available if there is a shortage of that medication

Whether delivered as a weekly injection like brand-name or compounded formulations or as oral drops , the pharmacological mechanism is the same